GDC-6036 is a covalent inhibitor of K-Ras containing a glycine-to-cysteine substitution at position 12 (K-RasG12C). It decreases tumor volume in a PaCa-2 pancreatic cancer mouse xenograft model when administered at doses ranging from 1 to 100 mg/kg per day.Formal Name:...

Description: Divarasib (GDC-6036) (GDC-6036) is an investigational, oral, high-potency and selective KRAS G12C inhibitor with an IC50 of < 0.01 µM. Divarasib irreversibly locks KRAS G12C oncoprotein in an inactive state and inhibits tumor cell growth. It is being investigated for use in solid tumors, including...